• Nenhum resultado encontrado

The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials

N/A
N/A
Protected

Academic year: 2019

Share "The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials"

Copied!
7
0
0

Texto

Loading

Imagem

Figure 1. Flow diagram of search strategy and study selection.
Table 1. Characteristics of the 7 studies in this meta-analysis comparing H. pylori eradication efficacy with moxifloxacin-based triple therapy vs standard triple or quadruple therapy.

Referências

Documentos relacionados

perform a systematic review and meta-analysis on the efficacy of all randomized controlled trials evaluating the efficacy of all avail- able endoscopic treatments when compared to

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic

OnabotulinumtoxinA 100 U signi fi cantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence:

Methods: This was a systematic review and meta-analysis of randomized clinical trials involving patients with stable, moderate to severe COPD according to the Global Initiative

Despite the limitations of this systematic review (e.g., few randomized clinical trials, low methodological quality of many of the included studies and the absence of

METHOD: A systematic review and meta-analysis were conducted of all randomized controlled trials published in English that compared compensatory sweating after lowering or

This study consists in a systematic review with meta-analysis of randomized clinical trials to as- sess the use of Omega 3 fatty acids for the treat- ment of hypertriglyceridemia

Methods: This was a systematic review and meta-analysis of randomized clinical trials involving patients with stable, moderate to severe COPD according to the Global Initiative